Montreal's enGene announces strategic collaboration with Johnson & Johnson for potential investment of C $441 million in therapeutics commercialization

engene_portfolio.png

MONTREAL, Oct. 14, 2015 /PRNewswire/ - enGene, Inc. a gene therapy company, enGene, focused on development of therapeutics using its proprietary "Gene Pill" and enema gene delivery platform, today announced that it has entered into a definitive agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize new therapies for inflammatory bowel disease (IBD). enGene is eligible to receive various pre-clinical, clinical, regulatory and commercialization success-based milestone payments up to a total of C $441 million, plus tiered royalties on potential net sales of products. 

Click here for full article.